Study design and population
ARDS
ARDS
This phase IIb, randomized, double-blind, placebo-controlled clinical trial was performed in four academic and non-academic ICUs in the Netherlands between March 2021 and March 2022 (Fig. Patient screening and inclusion. Screening and inclusion flowchart. Of the 67 randomized patients, 66 patients were included in the final analysis and 64 patients received at least one dose of the study medicationPatients were eligible if aged ≥ 18 years, intubated for invasive ventilation and had moderate-to-severe ARDS due to COVID-19. ARDS was classified according to Berlin criteria [